Aspire Biopharma (NASDAQ:ASBP – Get Free Report) and Lear (NYSE:LEA – Get Free Report) are both consumer discretionary companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.
Earnings and Valuation
This table compares Aspire Biopharma and Lear”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aspire Biopharma | $10,000.00 | 998.20 | -$24.48 million | ($69.62) | -0.10 |
| Lear | $23.79 billion | 0.21 | $436.80 million | $11.45 | 8.90 |
Institutional & Insider Ownership
19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 97.0% of Lear shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 1.0% of Lear shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Aspire Biopharma and Lear’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aspire Biopharma | -11,362.21% | N/A | -177.59% |
| Lear | 2.46% | 14.92% | 5.10% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Aspire Biopharma and Lear, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Lear | 0 | 12 | 3 | 1 | 2.31 |
Lear has a consensus price target of $143.25, indicating a potential upside of 40.52%. Given Lear’s stronger consensus rating and higher possible upside, analysts plainly believe Lear is more favorable than Aspire Biopharma.
Volatility and Risk
Aspire Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Lear has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
Summary
Lear beats Aspire Biopharma on 13 of the 15 factors compared between the two stocks.
About Aspire Biopharma
Aspire Biopharma is a biopharmaceutical company developing drug products that use sublingual delivery, in which a medicine is placed under the tongue for absorption. Its platform is intended to create rapidly absorbed formulations of existing drugs. The company has highlighted sublingual formulations based on aspirin and caffeine among its product candidates. These are under development; Aspire’s focus is on developing potential therapies rather than marketing an established portfolio of approved products.
About Lear
Lear Corporation is a global automotive technology supplier that designs and manufactures products for vehicle seating and electrical systems. Its customers include automakers around the world, and its products are used in a range of vehicle types. The company’s seating business provides complete seating systems and components, including seat structures, mechanisms, foam and trim. Its E-Systems business develops electrical distribution systems, connectivity solutions and electronic components that help manage power and data within vehicles.
Receive News & Ratings for Aspire Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspire Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
